Teva Pharmaceutical Industries Ltd. — Earnings Release 2011

Feb 8, 2011

==> picture [261 x 64] intentionally omitted <==

TEVA PROVIDES 2011 NON-GAAP FINANCIAL OUTLOOK

Jerusalem, Israel, February 8, 2011 - On its conference call today, Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) provided current outlook for its non-GAAP financial performance in 2011.

For the full year, Teva expects net sales to be between $18.5 billion and $19.0 billion, with nonGAAP earnings per share (EPS) to be in the range of $4.90 to $5.20. Teva expects the second half of 2011 to be stronger than the first half and the second quarter to be stronger than the first quarter of 2011. Quarterly net sales and EPS results are expected to improve sequentially.

In addition, Teva expects the following factors to impact its 2011 financial results –

• Non-GAAP gross profit margin (which excludes amortization of intangible assets of approximately $600 million) is expected to be in the range of 57.5% and 59.5%.

• Net R&D expenses (excluding reimbursement from third parties for certain R&D expenses and other investments) are expected to be approximately 6% of net sales.

• Non-GAAP selling & marketing expenses (which excludes amortization of intangible assets), are expected to be in the range of 18% to 19% of sales. In 2011 selling and marketing expenses include royalties totaling between $900 million to $950 million.

• General and administrative expenses are expected to be approximately 5% of sales.

• Non-GAAP finance expenses are expected to be between $40 million and $50 million per quarter.

• The non-GAAP tax rate is expected to be approximately 13%.

• Share in losses of associated companies is expected to be approximately $40 million to $45 million, resulting primarily from TL Biopharmaceuticals AG, our joint venture with Lonza, mostly related to R&D expenses.

• The fully diluted number of shares in 2011 is expected to be between 900 million and 910 million shares, depending on the execution of Teva’s share repurchase plan.

These estimates reflect management’s current expectations for Teva's performance in 2011. The actual non-GAAP results achieved are subject to the business environment and foreign currency fluctuations. The non-GAAP data presented by Teva are the results used by Teva's management and board of directors to evaluate the operational performance of the company, to compare against the company's work plans and budgets, and ultimately to evaluate the performance of management. Teva provides such non-GAAP data to investors as supplemental data and not in substitution or replacement for GAAP results, because management believes such data provides useful information to investors.

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic

==> picture [478 x 82] intentionally omitted <==

==> picture [261 x 64] intentionally omitted <==

drug maker, with a global product portfolio of more than 1,250 molecules and a direct presence in approximately 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs approximately 40,000 people around the world and reached $16.1 billion in net sales in 2010.

Teva's Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which we may obtain U.S. market exclusivity for certain of our new generic products and regulatory changes that may prevent us from utilizing exclusivity periods, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Neurontin®, Lotrel®, Protonix® and Gemzr®, the extent to which any manufacturing or quality control problems damage our reputation for high quality production, the effects of competition on sales of our innovative products, especially Copaxone® (including potential generic and oral competition for Copaxone®), the impact of continuing consolidation of our distributors and customers, our ability to identify, consummate and successfully integrate acquisitions (including the acquisition of ratiopharm), interruptions in our supply chain or problems with our information technology systems that adversely affect our complex manufacturing processes, intense competition in our specialty pharmaceutical businesses, any failures to comply with the complex Medicare and Medicaid reporting and payment obligations, our exposure to currency fluctuations and restrictions as well as credit risks, the effects of reforms in healthcare regulation, adverse effects of political or economical instability, major hostilities or acts of terrorism on our significant worldwide operations, increased government scrutiny in both the U.S. and Europe of our agreements with brand companies, dependence on the effectiveness of our patents and other protections for innovative products, our ability to achieve expected results through our innovative R&D efforts, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, uncertainties surrounding the legislative and regulatory pathway for the registration and approval of biotechnology-based products, potentially significant impairments of intangible assets and goodwill, potential increases in tax liabilities resulting from challenges to our intercompany arrangements, our potential exposure to product liability claims to the extent not covered by insurance, the termination or expiration of governmental programs or tax benefits, current economic conditions, any failure to retain key personnel or to attract additional executive and managerial talent, environmental risks and other factors that are discussed in this report and in our other filings with the U.S. Securities and Exchange Commission.

# # #

==> picture [478 x 82] intentionally omitted <==

, 20118 בפברואר

==> picture [261 x 64] intentionally omitted <==

non-GAAP לפי טבע מספקת תחזית פיננסית לשנת2011

. לשנת2011 non-GAAPלפי עדכנה טבע את התחזית הפיננסית שלה , בשיחת הוועידה שערכה היום

יהיהnon-GAAP לפיEPSוכי ה-, מיליארד דולר19.0 יסתכמו בטווח של בין18.5 ל- טבע צופה כי המכירות לשנת2011 תהינה חזקות מתוצאות המחצית טבע צופה כי תוצאות המחצית השניה של 2011. דולר 5.20 ווח של 4.80 דולר עדבט ישתפרו EPSהמכירות הרבעוניות וה-. ותוצאות הרבעון השני יהיו חזקות יותר מתוצאות הרבעון הראשון הראשונה . בהדרגה במהלך השנה

:ו על התוצאות הפיננסיות לשנת 2011טבע צופה כי הגורמים הבאים ישפיע, בנוסף ינוע בטווח של ( מיליון דולר600כ- של ) שאינו כולל הפחתת נכסים בלתי מוחשייםnon-GAAP הרווח גולמי לפי  . עד59.5%57.5% 6%יהוו כ-( פ מצדדים שלישיים והשקעות אחרות"שאינן כוללות החזר על הוצאות מו) הוצאות מחקר ופיתוח נטו  . מהמכירות עד19% צפויות להיות בטווח של 18%( שאינן כוללות הפחתת נכסים בלתי מוחשיים)שיווק ו הוצאות מכירה  מיליון מיליון דולר עד950 בסך כולל של 900לשנת 2011 כוללות תמלוגיםמכירה ושיווק הוצאות . מהמכירות .דולר .רבעוןבכל מיליון דולר50ו- מיליון דולרבין 40 צפויות להיותnon-GAAP הוצאות המימון לפי  .13% צפוי להיות כ-non-GAAP שיעור המס לפי   בעיקר כתוצאה , 45 מיליון דולר ההשתתפות בהפסדים של חברות הקשורות לטבע צפויה להיות בין40 ל- . ,המיזם המשותף של טבע ולונזהTL Biopharmaceuticals AGמ-מהוצאות מחקר ופיתוח של תוכנית הרכישה לביצוע בהתאם , 910 מיליון מניות צפוי להיות בין900 ל- 2011 מלא ב- מספר המניות בדילול  . העצמית של מניות טבע

non-GAAP .תוצאות ה2011 את ההערכות הנוכחיות של הנהלת טבע ביחס לתוצאות החברה ב-ות משקפההערכות אל המוצגים לעיל הם הנתונים בהם non-GAAPלפי הנתונים. שיושגו תלויות בתנאים עסקיים ושינויים בשערי חליפין להשוותם כנגד תוכנית העבודה , הנהלת טבע וחברי הדירקטוריון להעריך את התוצאות התפעוליות של החברהמשתמשת בנוסף ולא במקום non-GAAPטבע מספקת למשקיעיה את נתוני ה-. ולהעריך את ביצועי ההנהלה, ותקציבי החברה זאת מאחר שהנהלת החברה מאמינה כי נתונים אלה מספקים מידע שימושי עבור ציבור ,U.S. GAAPהתוצאות לפי . המשקיעים של החברה

טבע אודות תרופות ולשיווק לפיתוח המחויבת גלובלית תרופות חברת (היאTEVA: ק"נאסד ) מ" בע פרמצבטיות תעשיות טבע ייחודיות תרופות, גנריות תרופות ביצור עוסקת, שראלבי שבסיסה, החברה. בעולם מקום בכל יד בהישג גבוהה באיכות נוכחות עם , העולמי הגנריות התרופות שוק את מובילה טבע. הפרמצבטית לתעשייה פעילים גלם חומרי ובייצור וממותגות הייחודיים המוצרים. בעולם 100 מדינות מ- ביותר הנמכר 1,250 מולקולות מ- יותר של מוצרים סל ועם 60 מדינותבכ. הביולוגיות התרופות בתחום גם כמו, האישה ובריאות הנשימה, הנוירולוגיה בתחומי מתמקדים החברה של והממותגים . הנפוצה הטרשת במחלת לטיפול בתחומו המוביל המוצר ( ,הואCopaxone® )קופקסון, טבע של הייחודיים המוצרים בין . דולר 16.1 מיליארדנת 2010 ב-בש הסתכמו החברה מכירות. 40,000 איש כ-כיום מעסיקה טבע

Teva's Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize additional pharmaceutical

==> picture [478 x 82] intentionally omitted <==

==> picture [261 x 64] intentionally omitted <==

products, the introduction of competing generic equivalents, the extent to which we may obtain U.S. market exclusivity for certain of our new generic products and regulatory changes that may prevent us from utilizing exclusivity periods, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Neurontin®, Lotrel®, Protonix® and Gemzr®, the extent to which any manufacturing or quality control problems damage our reputation for high quality production, the effects of competition on sales of our innovative products, especially Copaxone® (including potential generic and oral competition for Copaxone®), the impact of continuing consolidation of our distributors and customers, our ability to identify, consummate and successfully integrate acquisitions (including the acquisition of ratiopharm), interruptions in our supply chain or problems with our information technology systems that adversely affect our complex manufacturing processes, intense competition in our specialty pharmaceutical businesses, any failures to comply with the complex Medicare and Medicaid reporting and payment obligations, our exposure to currency fluctuations and restrictions as well as credit risks, the effects of reforms in healthcare regulation, adverse effects of political or economical instability, major hostilities or acts of terrorism on our significant worldwide operations, increased government scrutiny in both the U.S. and Europe of our agreements with brand companies, dependence on the effectiveness of our patents and other protections for innovative products, our ability to achieve expected results through our innovative R&D efforts, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, uncertainties surrounding the legislative and regulatory pathway for the registration and approval of biotechnology-based products, potentially significant impairments of intangible assets and goodwill, potential increases in tax liabilities resulting from challenges to our intercompany arrangements, our potential exposure to product liability claims to the extent not covered by insurance, the termination or expiration of governmental programs or tax benefits, current economic conditions, any failure to retain key personnel or to attract additional executive and managerial talent, environmental risks and other factors that are discussed in this report and in our other filings with the U.S. Securities and Exchange Commission.

# # #

==> picture [478 x 82] intentionally omitted <==